| Ident. | Authors (with country if any) | Title |
|---|
| 000076 |
M. Lagière [France] ; S. Navailles [France] ; L. Mignon [États-Unis] ; A. Roumegous [France] ; M.-F. Chesselet [États-Unis] ; P. De Deurwaerdère [France] | The enhanced oral response to the 5-HT2 agonist Ro 60-0175 in parkinsonian rats involves the entopeduncular nucleus: electrophysiological correlates |
| 000109 |
Omar Ouachikh [France] ; Wisam Dieb [France] ; Franck Durif [France] ; Aziz Hafidi [France] | Differential behavioral reinforcement effects of dopamine receptor agonists in the rat with bilateral lesion of the posterior ventral tegmental area |
| 000267 |
Sophie Bayard [France] ; Valérie Cochen De Cock [France] ; Yves Dauvillers [France] | Le syndrome de dysrégulation dopaminergique dans la maladie de Parkinson et le syndrome des jambes sans repos |
| 000272 |
L. Bindler [France] ; M. Anheim [France] ; C. Tranchant [France] ; P. Vidailhet [France] | La créativité du patient parkinsonien |
| 000353 |
Ngoc-Duc Doan [Canada] ; Steve Bourgault [Canada] ; Agnieszka Dejda [Canada] ; Myriam Letourneau [Canada] ; Michel Detheux [Belgique] ; David Vaudry [Canada, France] ; Hubert Vaudry [Canada, France] ; David Chatenet [Canada] ; Alain Fournier [Canada] | Design and in vitro characterization of PAC1/VPAC1-selective agonists with potent neuroprotective effects |
| 000502 |
Santiago Perez-Lloret [France, Argentine] ; Olivier Rascol [France] | Dopamine Receptor Agonists for the Treatment of Early or Advanced Parkinson's Disease |
| 000507 |
A. Faure [France] ; P. Leblanc-Veyrac [France] ; N. El Massioui [France] | DOPAMINE AGONISTS INCREASE PERSEVERATIVE INSTRUMENTAL RESPONSES BUT DO NOT RESTORE HABIT FORMATION IN A RAT MODEL OF PARKINSONISM |
| 000592 |
S. Bourgault [Canada, France] ; D. Vaudry [France] ; A. Dejda [Canada, France] ; N. D. Doan [Canada, France] ; H. Vaudry [France] ; A. Fournier [Canada, France] | Pituitary Adenylate Cyclase-Activating Polypeptide: Focus on Structure-Activity Relationships of a Neuroprotective Peptide |
| 000680 |
Pierre Cesaro [France] | Neuroprotection et maladie de Parkinson |
| 000695 |
J.-M. Gerard [France] | Initiation du traitement de la maladie de Parkinson et son adaptation en fonction de l'évolution |
| 000737 |
Dieter Scheller [Allemagne] ; Christine Stichel-Gunkel [Allemagne] ; Hermann Lübbert [Allemagne] ; Gregory Porras [France] ; Paula Ravenscroft [Royaume-Uni] ; Michael Hill [Royaume-Uni] ; Erwan Bezard [France, Royaume-Uni] | Neuroprotective effects of rotigotine in the acute MPTP-lesioned mouse model of Parkinson's disease |
| 000777 |
A. Marighetto [France] ; S. Valerio [France] ; J. N. Philippin [France] ; V. Bertaina-Anglade [France] ; C. Drieu La Rochelle [France] ; R. Jaffard [France] ; P. Morain [France] | Comparative effects of the dopaminergic agonists piribedil and bromocriptine in three different memory paradigms in rodents |
| 000845 |
Pauline Sibille [France] ; Sébastien Lopez [France] ; Isabelle Brabet [France] ; Omella Valenti [États-Unis] ; Nadia Oueslati [France] ; Florence Gaven [France] ; Cyril Goudet [France] ; Hugues-Olivier Bertrand [France] ; Jacques Neyton [France] ; Michael J. Marino [États-Unis] ; Marianne Amalric [France] ; Jean-Philippe Pin [France] ; Francine C. Acher [France] | Synthesis and biological evaluation of 1 -amino -2 -phosphonomethylcyclopropanecarboxylic acids, new group III metabotropic glutamate receptor agonists |
| 000875 |
Heike Wulff [États-Unis] ; Aaron Kolski-Andreaco [États-Unis] ; Ananthakrishnan Sankaranarayanan [États-Unis] ; Jean-Marc Sabatier [France] ; Vikram Shakkottai [États-Unis] | Modulators of small- and intermediate-conductance calcium-activated potassium channels and their therapeutic indications |
| 000937 |
Jean-Louis Montastruc [France] ; Agnès Sommet [France] ; Pascale Olivier [France] ; Haieh Bagheri [France] ; Mireille Gony [France] ; Maryse Lapeyre-Mestre [France] ; Christine Brefel-Courbon [France] ; Joachim Ferreira [Portugal] ; Laurent Schmitt [France] ; Jean-Michel Senard [France] ; Olivier Rascol [France] | Médicaments, maladie de Parkinson et syndromes parkinsoniens : actualités de pharmacovigilance |
| 000984 |
Dominique Drapier [France] ; Sophie Drapier [France] ; Paul Sauleau [France] ; Pascal Derkinderen [France] ; Philippe Damier [France] ; Herve Allain [France] ; Marc Verin [France] ; Bruno Millet [France] | Pathological gambling secondary to dopaminergic therapy in Parkinson's disease |
| 000C85 |
F. Ghawche [France] ; F. Durif [France] | Traitement dopaminergique et syndromes parkinsoniens |
| 000D22 |
J.-L. Montastruc [France] ; L. Schmitt [France] ; H. Bagheri [France] | Comportement pathologique de jeu au cours d'une maladie de Parkinson traitée par lévodopa et bromocriptine |
| 000D41 |
R. Bordet [France] ; D. Devos [France] ; S. Brique [France] ; Y. Touitou [France] ; J. D. Guieu [France] ; C. Libersa [France] ; A. Destee [France] | Study of circadian melatonin secretion pattern at different stages of Parkinson's disease |
| 000D42 |
Alan L. Whone [Royaume-Uni] ; Ray L. Watts [États-Unis] ; A. Jon Stoessl [Canada] ; Margaret Davis [États-Unis] ; Sven Reske [Allemagne] ; Claude Nahmias [Canada] ; Anthony E. Lang [Canada] ; Olivier Rascol [France] ; Maria J. Ribeiro [France] ; Philippe Remy [France] ; Werner Poewe [Autriche] ; Robert A. Hauser [États-Unis] ; David J. Brooks [Royaume-Uni] | Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study |
| 000D80 |
Marc Ziegler [France] ; Alexandre Castro-Caldas [Portugal] ; Susanna Del Signore [France] ; Olivier Rascol [France] | Efficacy of Piribedil as early combination to levodopa in patients with stable Parkinson's disease: A 6-month, randomized, placebo-controlled study |
| 000D81 |
G. Fenelon [France] ; S. Gimenez-Roldan [Espagne] ; J. L. Montastruc [France] ; F. Bermejo [Espagne] ; F. Durif [France] ; I. Bourdeix [France] ; J.-J. Pere [Espagne] ; L. Galiano [Suisse] ; J. Schadrack | Efficacy and tolerability of entacapone in patients with Parkinson's disease treated with levodopa plus a dopamine agonist and experiencing wearing-off motor fluctuations. A randomized, double-blind, multicentre study |
| 000E14 |
| Parkinson et mouvements anormaux |
| 000E28 |
A. Destee [France] ; R. Bordet [France] | Stimulation dopaminergique continue, stimulation dopaminergique pulsatile |
| 000E32 |
J. L. Montastruc [France] ; O. Rascol [France] | Propriétés pharmacodynamiques des agonistes dopaminergiques ? Quelle transférabilité en pratique clinique dans le traitement de la maladie de Parkinson ? |
| 000E33 |
O. Rascol [France] ; J.-J. Ferreira [Portugal] ; P. Payoux [France] ; Ch. Brefel-Courbon [France] ; J.-L. Montastruc [France] | Prise en charge des dyskinésies par la lévodopa |
| 000E49 |
A.-M. Bonnet [France] ; J.-L. Houeto [France] | Le pergolide: un agoniste utile dans le traitement de la maladie de Parkinson |
| 000E63 |
F. Durif [France] | Fluctuations motrices |
| 000E92 |
Lance A. Smith [Royaume-Uni] ; Banu C. Tel [Royaume-Uni] ; Michael J. Jackson [Royaume-Uni] ; Matthew J. Hansard [Royaume-Uni] ; Rogelio Braceras [Royaume-Uni] ; Céline Bonhomme [France] ; Claire Chezaubernard [France] ; Susanna Del Signore [France] ; Sarah Rose [Royaume-Uni] ; Peter Jenner [Royaume-Uni] | Repeated administration of Piribedil induces less dyskinesia than L-dopa in MPTP-treated common marmosets: A behavioural and biochemical investigation |
| 000F26 |
Marie-Paule Muriel [France] ; Gaël Orieux [France] ; Etienne C. Hirsch [France] | Levodopa but not ropinirole induces an internalization of D1 dopamine receptors in Parkinsonian rats |
| 000F34 |
A. Angles [France] ; H. Bagheri [France] ; S. Saivin [France] ; J. L. Montastruc [France] | Interaction between lansoprazole and bromocriptine in a patient with Parkinson's disease |
| 000F48 |
A. D. Korczyn [Israël] ; C. Thalamas [France] ; C. H. Adler [États-Unis] | Dosing with ropinirole in a clinical setting |
| 000F63 |
C. Lebrun-Frenay [France] ; M. Borg [France] | Choosing the right dopamine agonist for patients with Parkinson's disease |
| 000F80 |
K. Ray Chaudhuri [Royaume-Uni] ; Suvankar Pal [Royaume-Uni] ; Christine Brefel-Courbon [France] | 'Sleep attacks' or 'Unintended sleep episodes' occur with dopamine agonists: Is this a class effect? |
| 001030 |
Jean-Louis Montastruc [France] ; Christine Brefel-Courbon [France] ; Jean-Michel Senard [France] ; Haleh Bagheri [France] ; Joaquim Ferreira [France] ; Olivier Rascol [France] ; Maryse Lapeyre-Mestre [France] | Sleep attacks and antiparkinsonian drugs : A pilot prospective pharmacoepidemiologic study |
| 001056 |
Peter Brown [Royaume-Uni] ; Jon Marsden [Royaume-Uni] ; Luc Defebvre [France] ; Francois Cassim [France] ; Paolo Mazzone [Italie] ; Antonio Oliviero [Italie] ; Maria Grazia Altibrandi [Italie] ; Vincenzo Di Lazzaro [Italie] ; Patricia Limousin-Dowsey [Royaume-Uni] ; Valerie Fraix [France] ; Per Odin [Allemagne] ; Pierre Pollak [France] | Intermuscular coherence in Parkinson's disease : relationship to bradykinesia |
| 001080 |
Thomas Boraud [France] ; Erwan Bezard [France] ; Bernard Bioulac [France] ; Christian E. Gross [France] | Dopamine agonist-induced dyskinesias are correlated to both firing pattern and frequency alterations of pallidal neurones in the MPTP-treated monkey |
| 001085 |
Alberto Albanese [Italie] ; Ubaldo Bonuccelli [Italie] ; Christine Brefel [France] ; K. Ray Chaudhuri [Royaume-Uni] ; Carlo Colosimo [Italie] ; Tobias Eichhorn [Allemagne] ; Eldad Melamed [Israël] ; Pierre Pollak [France] ; Teus Van Laar [Pays-Bas] ; Mario Zappia [Italie] | Consensus statement on the role of acute dopaminergic challenge in Parkinson's disease |
| 001114 |
P. Derkinderen [France] | Stratégies thérapeutiques conseillées à la phase initiale de la maladie |
| 001143 |
O. Rascol [France] ; J.-L. Montastruc [France] | La place des agonistes dopaminergiques |
| 001172 |
L. A. Smith [Royaume-Uni] ; M. G. Jackson [Royaume-Uni] ; C. Bonhomme [France] ; C. Chezaubernard [France] ; K. B. Pearce [Royaume-Uni] ; P. Jenner [Royaume-Uni] | Transdermal administration of piribedil reverses MPTP-induced motor deficits in the common marmoset |
| 001196 |
O. Rascol [France] | Medical treatment of levodopa-induced dyskinesias |
| 001216 |
H. Allain [France] ; A. Destee [France] ; H. Petit [France] ; M. Patay [France] ; S. Schück [France] ; D. Bentue-Ferrer [France] ; P. Le Cavorzin [France] | Five-year follow-up of early lisuride and levodopa combination therapy versus levodopa monotherapy in de novo Parkinson's disease |
| 001233 |
C. Imbert [France] ; E. Bezard [France] ; S. Guitraud [France] ; T. Boraud [France] ; C. E. Gross [France] | Comparison of eight clinical rating scales used for the assessment of MPTP-induced parkinsonism in the Macaque monkey |
| 001242 |
D. C. Rogers [Royaume-Uni] ; B. Costall [Royaume-Uni] ; A. M. Domeney [France] ; P. A. Gerrard [Royaume-Uni] ; M. Greener [Royaume-Uni] ; M. E. Kelly [Royaume-Uni] ; J. J. Hagan [Royaume-Uni] ; A. J. Hunter [Royaume-Uni] | Anxiolytic profile of ropinirole in the rat, mouse and common marmoset |
| 001248 |
O. Rascol [France] ; D. J. Brooks [Royaume-Uni] ; A. D. Korczyn [Israël] ; P. P. De Deyn [Belgique] ; C. E. Clarke [Royaume-Uni] ; A. E. Lang [Canada] | A five-year study of the incidence of dyskinesia in patients with early parkinson's disease who were treated with ropinirole or levodopa |
| 001282 |
G. L. Defer [France] | Controverse sur le traitement initial de la maladie de parkinson : L-dopa ou agonistes dopaminergiques ? |
| 001283 |
O. Rascol [France] | Arguments en faveur du traitement précoce de la maladie de Parkinson par les agonistes dopaminergiques |
| 001286 |
M. Ziegler [France] ; P. Rondot [France] | Activité du piribédil dans la maladie de Parkinson : Etude multicentrique |
| 001290 |
J. L. Montastruc [France] ; O. Rascol [France] ; J.-M. Senard [France] | Treatment of Parkinson's disease should begin with a dopamine agonist |
| 001342 |
| Efficacy and tolerability of tolcapone compared with bromocriptine in levodopa-treated Parkinsonian patients |
| 001344 |
O.-K. Hassani [France] ; J. Feger [France] | Effects of intrasubthalamic injection of dopamine receptor agonists on subthalamic neurons in normal and 6-hydroxydopamine-lesioned rats : An electrophysiological and C-fos study |
| 001355 |
S. Champagne [France] ; E. Coste [France] ; H. Peyriere [France] ; J. Nigond [France] ; E. Mania [France] ; M. Pons [France] ; D. Hillaire-Buys [France] ; P. Balmes [France] ; J.-P. Blayac [France] ; J.-M. Davy [France] | Chronic constrictive pericarditis induced by long-term bromocriptine therapy : Report of two cases |
| 001369 |
O. Rascol [France] ; O. Blin [France] ; C. Thalamas [France] ; S. Descombes [France] ; C. Soubrouillard [France] ; P. Azulay [France] ; N. Fabre [France] ; F. Viallet [France] ; K. Lafnitzegger [États-Unis] ; S. Wright [États-Unis] ; J. H. Carter [États-Unis] ; J. G. Nutt [États-Unis] | ABT-431, a D1 receptor agonist prodrug, has efficacy in Parkinson's Disease |
| 001371 |
H. Bagheri [France] ; C. Damase-Michel [France] ; M. Lapeyre-Mestre [France] ; S. Cismondo [France] ; D. O'Connell [Irlande (pays)] ; J.-M. Senard [France] ; O. Rascol [France] ; J.-L. Montastruc [France] | A study of salivary secretion in Parkinson's disease |
| 001373 |
J.-L. Montastruc [France] ; M. Ziegler [France] ; O. Rascol [France] ; M. Malbezin [France] | A randomized, double-blind study of a skin patch of a dopaminergic agonist, piribedil, in Parkinson's disease |
| 001386 |
O. Rascol [France] ; C. Brefel-Courbon [France] ; O. Blin [France] | Pharmacologie clinique des dyskinésies induites par la L-dopa chez les malades parkinsoniens |
| 001403 |
J. M. Senard [France] ; J. L. Montastruc [France] | Approche pharmacologique des dysautonomies |
| 001416 |
A. E. Schrag [Royaume-Uni] ; D. J. Brooks [Royaume-Uni] ; E. Brunt [Pays-Bas] ; D. Fuell [Royaume-Uni] ; A. Korczyn [Israël] ; Werner Poewe [Autriche] ; N. P. Quinn [Royaume-Uni] ; O. Rascol [France] ; F. Stocchi [Italie] | The safety of ropinirole, a selective nonergoline dopamine agonist, in patients with Parkinson's disease |
| 001421 |
A. D. Korczyn [Israël] ; D. J. Brooks [Royaume-Uni] ; E. R. Brunt [Pays-Bas] ; Werner Poewe [Autriche] ; O. Rascol [France] ; F. Stocchi [Italie] | Ropinirole versus bromocriptine in the treatment of early Parkinson's disease : A 6-month interim report of a 3-year study |
| 001422 |
O. Rascol [France] ; D. J. Brooks [Royaume-Uni] ; E. R. Brunt [Pays-Bas] ; A. D. Korczyn [Israël] ; Werner Poewe [Autriche] ; F. Stocchi [Italie] | Ropinirole in the treatment of early Parkinson's disease : A 6-month interim report of a 5-year levodopa-controlled study |
| 001454 |
C. Brefel [France] ; C. Thalamas [France] ; S. Rayet [France] ; A. Lopez-Gil [Royaume-Uni] ; K. Fitzpatrick [Royaume-Uni] ; S. Bullman [Royaume-Uni] ; D. R. Citerone [Royaume-Uni] ; A. C. Taylor [Royaume-Uni] ; J. L. Montastruc [France] ; O. Rascol [France] | Effect of food on the pharmacokinetics of ropinirole in parkinsonian patients |
| 001466 |
M.-A. Bedard [Canada] ; F. El Massioui [France] ; C. Malapani [France] ; B. Dubois [France] ; B. Pillon [France] ; B. Renault [France] ; Yves Agid [France] | Attentional deficits in Parkinson's disease : Partial reversibility with naphtoxazine (SDZ NVI-085), a selective noradrenergic α1 agonist |
| 001469 |
D. J. Brooks [Royaume-Uni] ; R. J. Abbott [Royaume-Uni] ; A. J. Lees [Royaume-Uni] ; E. Martignoni [Italie] ; D. V. Philcox [Afrique du Sud] ; O. Rascol [France] ; R. A. C. Roos [Pays-Bas] ; H. J. Sagar [Royaume-Uni] | A placebo-controlled evaluation of ropinirole, a novel D2 agonist, as sole dopaminergic therapy in Parkinson's disease |
| 001535 |
C. Soubrouillard [France] ; C. Lombardo [France] ; O. Rascol [France] ; B. Bruguerolle [France] ; O. Blin [France] | Agonistes dopaminergiques centraux D1 et traitement de la maladie de Parkinson |
| 001543 |
Yves Agid [France] ; A. Destee ; F. Durif ; J.-L. Montastruc ; P. Pollak | Tolcapone, bromocriptine, and Parkinson's disease |
| 001555 |
E. Courty [France] ; F. Durif [France] ; M. Zenut [France] ; P. Courty [France] ; J. Lavarenne [France] | Psychiatric and sexual disorders induced by apomorphine in Parkinson's disease |
| 001582 |
F. Coudore [France] ; F. Durif [France] ; E. Duroux [France] ; A. Eschalier [France] ; J. Fialip [France] | Effect of tolcapone on plasma and striatal apomorphine disposition in rats |
| 001618 |
P. Morel [France] | Les perspectives thérapeutiques de la maladie de Parkinson |
| 001636 |
O. Rascol [France] ; A. J. Lees ; J. M. Senard [France] ; Z. Pirtosek ; J. L. Montastruc [France] ; D. Fuell | Ropinirole in the treatment of levodopa-induced motor fluctuations in patients with Parkinson's disease |
| 001653 |
F. Tison [France] ; L. Wiart [France] ; M. Guatterie [France] ; N. Fouillet [France] ; V. Lozano [France] ; P. Henry [France] ; M. Barat [France] | Effects of central dopaminergic stimulation by apomorphine on swallowing disorders in Parkinson's disease |
| 001740 |
D. Muguet [France] ; E. Broussolle ; G. Chazot | Apomorphine in patients with Parkinson's disease : Parkinson's disease |
| 001745 |
A. M. Bonnet [France] ; I. Serre [France] ; R. Marconi [France] ; Yves Agid [France] ; B. Dubois [France] | A "combined" levodopa test as a useful method for evaluating the efficacy of dopamine agonists : application to pergolide and bromocriptine |
| 001940 |
P. Pollak [France] ; C. L. Gervason ; D. Deffond ; J. E. Perret | Apomorphine et maladie de Parkinson : un progrès thérapeutique majeur |
| 001A38 |
A. Vamvakides | Hypothèse de travail sur l'effet des dérivés GABAergiques, glycinergiques ou glutamatergiques dans le traitement de la maladie de Parkinson |
| 001A64 |
J. Hugon [France] ; J. M. Vallat | Abnormal distribution of phosphorylated neurofilaments in neuronal degeneration induced by kainic acid |
| 001B94 |
G. Bartholini | GABA receptor agonists: pharmacological spectrum and therapeutic actions |
